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chamber.The concept of CTDI is still the basis for dosimetry at modern 
CT scanners, although the assessment of CTDI in phantoms has been 
the subject of much discussion and many revisions were required since 
its initial definition. A fundamental revision was for example needed 
when helical CT was introduced and the concept of pitch had to be 
taken into account. With the introduction of diagnostic wide CT 
beams and the introduction of cone beam computed tomography 
(CBCT) with CT scanners that are integrated with a linear accelerator 
a new problem arose. For these wide CT beams nor the CT dose 
phantoms nor the 100 mm long pencil ionization chamber were 
compatible with the at that time prevailing concept of CTDI. The 
problem was that the beam width of diagnostic wide beam scanners 
and CBCT scanners exceeds the lenght of the cylindrical CT phantoms 
(typically150 mm) and length of the pencil CT ionization chamber (100 
mm) (Geleijns etal.; Wen et al.). 
Solution for diagnostics wide cone beam CT scanners 
As a development to overcome the shortcomings described in the 
previous section, the proposed IEC 60601-2-44 international standard 
(Amendment1 of Edition 3) describes a two tiered approach to the 
definition of CTDI. The first tier is for beam widths ≤ 40 mm and uses 
the conventional definition of CTDI100. In the second tier for beam 
widths > 40mm, it is proposed to measure a reference value for CTDI 
in the standard CT dose phantoms, for anominal beam width of about 
20 mm. This value is then scaled up by the ratio of free in air 
measurements of CTDI for the wide beam condition and the reference 
condition. This approach is also followed in the IAEA Human Health 
Report 5 and is supported by the scientific work from Boone. 
Kilovoltage cone beam CT at the linac’s are a special case since at a 
large field of view the detector is shifted from the centered position, 
this may complicate the measurement of CTDI considerably. 
Assessment of patient dose for cone beam CT scans at the linac’s is 
also complicated. Monte Carlo calculations or measurements with 
anthropomorphic phantoms may be performed. A pragmatic approach 
may be to adhere to the methodology that is often used for diagnostic 
CTscanners, i.e. to use a body part specific conversion factor for 
calculating effective dose from dose-length product. 
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According to the MIRD formalism: 
 
Where  is the absorbed dose in target k from source h, Ãh is 
the cumulated activity in source h, and  is the mean absorbed 
dose per unit cumulated activity from source h to target k (also known 
as "S factor"). This, in theory, divides the calculation of the absorbed 
dose in 2 steps: determination of cumulated activity and computation 
of the S factor. 
When Ãh is obtained from a group of patients, or healthy volunteers, 
or from extrapolation from animal data, and when is obtained 
from a model (anthropomorphic phantom), the resulting absorbed 
dose is therefore suited for model dosimetry, i.e. to provide for 
estimates of the absorbed dose delivered to an hypothetical patient, 
rather than the patient that actually benefited from the nuclear 
medicine procedure. That kind of approach corresponds to the 
situation of radiopharmaceutical administration in a diagnostics 
context, where the injected activity is not supposed to induce 
deterministic effects. The ICRP tables give, for each 
radiopharmaceutical, an estimate of the absorbed dose delivered per 
MBq injected. These should be used in nuclear medicine departments: 
every patient should be given an estimate of the absorbed dose 
delivered during the procedure, even in a diagnostic context. 
In a therapeutic context, the delivered absorbed doses are within the 
range of appearance of deterministic effects. It is therefore important 
to increase the level of accuracy for the determination of the 
absorbed dose. A first step to achieve that goal is to assess the 
radiopharmaceutical uptake for every patient. This requires 
quantitative imaging and pharmacokinetics assessment procedures, 
and thus provides for a specific determination of Ãh.  
However, it is not always possible to derive specific values 
for . A possible means is to adjust model-based S factors in 
order to increase the specificity of the calculation. There are several 
means to achieve this, however one should keep in mind that the end-
result will still be a model-based absorbed dose computation (more or 
less realistic, as a function of the hypothesis adopted for adjusting 
model-based S factors to a given patient). 
Finally, whenever possible, in a therapeutic context, a full patient-
specific dosimetry should be performed. This requires patient-specific 
activity – and cumulated activity – determination, and computation of 
patient-specific S factors. This is the only way to obtain a real 
patient-specific absorbed dose assessment. The availability of CT-
based geometry definition combined with the spread of radiation 
transport modeling codes and the ever-growing computing power 
available now make this option a viable one in a clinical context. 
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Population doses from radiodiagnostic (x-ray and nuclear medicine) 
procedures in Europe were estimated for the first time in the recent 
DOSE DATAMED 2 (DDM2) project (www.ddmed.eu) launched by the 
European Commission. Data of 36 countries was collected to an 
established database.  
The results of the data collection and analysis lead to the following 
conclusions of the overall total collective effective doses in European 
countries:   
For x-ray procedures in EU-countries and EFTA countires (Norway, 
Iceland and Switzerland) the collective effective dose is 544700 
manSv, or 1,065 manSv per 1000 of population, resulting in a mean 
effective dose of 1,07 mSv per caput.  For all European countries 
included in the DDM2 survey the collective effective dose was 605010 
manSv, or 1,052 manSv per 1000 of population, resulting in a mean 
effective dose of 1,05 mSv per caput.    
For NM procedures in EU-countries and EFTA countries the collective 
effective dose is 30781 manSv, or 60,2 manSv per milion of 
population, resulting in a mean effective dose of 0,060 mSv per 
caput.  For all European countries included in the DDM2 survey the 
collective effective dose is 31336 manSv, or 54,5 manSv per million of 
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population, resulting in a mean effective dose of 0,055 mSv per caput. 
The contribution of NM procedures to the total population dose is 
about 5 %.   
The overall per caput effective dose for all medical imaging (X-rays + 
NM procedures) is therefore 1,13 mSv for EU and EFTA countries and 
1,105 mSv for all European countries. These values are about half of 
the recent value of collective effective dose estimated in Australia 
and about one third of the corresponding value in the USA. However, 
comparing the results with an earlier estimation of population dose in 
Europe, in the DDM1 countries, there seems to be a trend upwards: 
the increase of per caput effective dose is on the average about 30 %.   
The overall collective effective doses of x-ray procedures per 1000 
populations can be seen in Fig.1 for different countries. The relative 
overall collective effective doses (% of the collective effective dose of 
all x-ray examinations), for the main groups of plain radiography, 
fluoroscopy, CT and IR, are also shown. It can be seen that computed 
tomography yields by far the highest contribution, on the average 57,0 
% (range 5,31 – 83,1 %), to the population dose in most countries, 
while the relative contributions of all main groups vary a lot between 
the countries.  
A relatively low value of population dose can be a good sign for a 
successful implementation of the justification and optimization 
principles in radiation protection, but it can also be related to the 
lack of imaging resources. A relatively high value, vice versa, should 
imply considerations on whether the justification and optimization are 
properly implemented. While the average dose in Europe turned out 
to be relatively low, there are high variations of the results between 
countries indicating that there is a need for further studies and follow 
up of the trends. It is important to investigate and ensure a proper 
balance between local imaging resources and optimal radiation 
protection. The distribution of the doses between various groups of 
examinations and other detailed results of this study can be exploited 
in comparing the practices and identifying the cases requiring highest 
attention.  
 
   
Fig. 1. Overall collective effective dose of x-ray procedures per 1000 
population for different countries.  The relative contributions of the 
four main groups (plain radiography, fluoroscopy, computed 
tomography and interventional radiology) are also shown.  
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Managing internal anatomy motion due to physiological random or 
quasi-periodical processes is a critical challenge in external beam 
radiation therapy especially in the context of single- or few-fraction 
ablative regiments for abdominal targets. Existing and emerging 
technologies for localizing abdominal targets during beam delivery 
employ tracking of implanted fiducial markers, tracking of external 
surrogates, or guidance via magnetic resonance images. However, 
these technologies cannot meet the challenge of providing real-time, 
volumetric, non-invasive, markerless soft-tissue image guidance to 
existing radiation delivery platforms.  
Diagnostic ultrasound is a safe, non-ionizing, non-invasive modality 
widely used in image-guided cancer interventions that has significant 
potential to address this challenge. Modern matrix array transducers 
can generate real-time soft-tissue single plane (2D), cross-plane, and 
volumetric (3D) data thus allowing optimization of frame rate, field-
of-view and image quality for the purposes of motion monitoring and 
tracking. Furthermore, digital navigation links that stream live data to 
other devices enable the development of real-time image-
guidance applications on dedicated interventional workstations with 
no interference to the imaging process.  
 
  
Figure 1.  Robotic manipulator combined with 4D ultrasound for real-
time image-guidance concurrent with beam delivery. 
 
Based on these capabilities we are developing and evaluating a novel 
approach that combines robotics with diagnostic ultrasound imaging 
(Figure 1). It uses a customized add-on human-safe robotic 
manipulator to control the force and position of an abdominal probe 
while avoiding gantry collisions. The transducer is optically tracked to 
localize the ultrasound images in the coordinate system of the 
delivery device. Image processing techniques are implemented to 
monitor anatomy displacements in real time. The approach is being 
evaluated with regard to imaging robustness, interference with 
delivery devices, impact on treatment plans, localization accuracy, 
and temporal lag.  
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Cone beam CT (CBCT) integrated with a linear accelerator has 
provided 3D and 4D soft tissue contrast for image guided 
radiotherapy. While volumetric imaging has considerably improved 
target alignment prior to treatment delivery, it has limited capacity 
to monitor target alignment during treatment delivery. 
Tomosynthesis, on the other hand, where projection data of only a 
sub-arc is reconstructed into a 2½D image has the potential to 
increase the temporal resolution of soft tissue imaging. To that end, 
Tomosynthesis reconstruction can be applied to projection data 
acquired during VMAT (Volumetric Modulated Arc Therapy) delivery or 
during gantry rotation between static IMRT beams. An overview will 
be given of Tomosynthesis reconstruction and registration techniques. 
Impact of respiratory motion on Tomosynthesis image quality and 
possible mitigation strategies will be presented. Trade-offs between 
temporal resolution and spatial resolution will be demonstrated and 
